Navigating Innovations: A Managed Care Perspective Addressing the Economic Burden of Schizophrenia

Program Description

Although treatments for schizophrenia have improved in recent decades, many standard treatments still have significant limitations. Treating schizophrenia requires a personalized approach beyond just medication, including early intervention to improve outcomes and prevent relapse as well as care coordination to ensure adherence and symptom management. Both negative and cognitive symptoms are central aspects of schizophrenia treatment, but traditional antipsychotic medications have limited efficacy against these symptoms. Additionally, the lack of recently updated guidelines for managing therapies in patients with schizophrenia has created barriers to treatment. This supplement explores opportunities to improve the integration of managed care professionals into the schizophrenia treatment paradigm, from diagnosis and symptom management to ensuring cost-effective care through value-based approaches. By facilitating appropriate use and access to emerging schizophrenia therapies, including prescription digital therapeutics, managed care professionals can play an important role in individualizing therapy and improving access to medications.

Target audience: Managed care pharmacists

Type of activity: Application
Release date: August 30, 2024
Expiration date: September 30, 2025

Time to complete activity: 3.0 hours

Learner level: Foundational
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain positive, negative, and cognitive symptoms of schizophrenia and the unmet needs in the management of schizophrenia.
• Explore the pharmacology, safety profiles, and clinical pearls of new and emerging therapies for the management of schizophrenia.
• Analyze clinical trial data of recently approved and emerging therapies and how they fit into the treatment paradigm of schizophrenia.
• Investigate value-based approaches to improve access to individualized treatment plans to address the clinical and economic burdens of disease.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 3.0 contact hours (0.30 CEU) under the ACPE universal activity number 0290-0000-24-219-H01-P. The activity is available for CE credit through September 30, 2025.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Faculty

Brian J. Miller, MD, PhD, MPH, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: Augusta University, National Institute of Mental Health, Stanley Medical Research Institute

Honoraria: Atheneum, Clearview

Megan Maroney, PharmD, BCPP, has the following financial relationships with commercial interests to disclose:
Consultant: Novus Medical Education

Advisory boards: Biogen and Sage Therapeutics, Boehringer Ingelheim

Khalid M. Kamal, MPharm, PhD, has the following financial relationships with commercial interests to disclose:
Grant/Research Support: EMD Serono, Cerevel Therapeutics

Consultant: Cytel/Pfizer

Medical Writing & Editorial Support

Anne Schock Erlich, PharmD; and Faria Munir, PharmD, MS

Shetal Desai, PharmD, has the following financial relationship with a commercial interest to disclose:

Stock: Gilead

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.

Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms